Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics will present a poster on the ALSTARS trial design at the 5th ALS Drug Development Summit in Boston on June 3, 2026. The presentation outlines the Phase 2, randomized, double-blind, placebo-controlled study of COYA 302 for the treatment of ALS.
Key figures
- Drug Name
- COYA 302
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.